Last updated on August 2019

S0820 Adenoma and Second Primary Prevention Trial


Brief description of study

The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second primary colorectal cancers in patients previously treated for Stages 0 through III colon or rectal cancer.

Detailed Study Description

The purpose of this study is to assess whether the combination of eflornithine 500 mg and sulindac 150 mg (compared to corresponding placebos) has efficacy against colorectal lesions with respect to high-grade dysplasia, adenomas with villous features, adenomas 1 cm or greater, multiple adenomas, any adenomas >/= 0.3 cm, total advanced colorectal events, or total colorectal events.

Clinical Study Identifier: NCT01349881

Find a site near you

Start Over

Valley Medical Oncology Consultants

Pleasanton, CA United States
2.07miles
  Connect »

Epic Care-Dublin

Dublin, CA United States
4.57miles
  Connect »

Kaiser Permanente Dublin

Dublin, CA United States
4.57miles
  Connect »